Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGER | Q15109 | 16/20 | 0.86 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.48 |
| ▸ | ATP4A | P20648 | 1/20 | 0.46 |
| ▸ | ATP4B | P51164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18650027 | 1.00 | AGER (0.86) | AGERCXCR1ATP4AATP4BHRH3 | |
| Azeliragon SCHEMBL1142599 | 0.92 | AGER (1.00) | AGERATP4AATP4BHRH3 | |
| SCHEMBL1283514 | 0.92 | AGER (1.00) | AGERATP4AATP4BHRH3 | |
| Azeliragon SCHEMBL1893545 | 0.92 | AGER (0.98) | AGERATP4AATP4BHRH3 | |
| SCHEMBL23631278 | 0.89 | AGER (1.00) | AGER | |
| SCHEMBL1283052 | 0.89 | AGER (0.77) | AGERATP4AATP4B | |
| Azeliragon SCHEMBL1767579 | 0.88 | AGER (0.91) | AGERATP4AATP4BHRH3 | |
| SCHEMBL18649819 | 0.88 | AGER (0.68) | AGERCXCR1ATP4AATP4BHRH3 | |
| SCHEMBL18650011 | 0.87 | AGER (0.79) | AGER | |
| SCHEMBL12649489 | 0.87 | AGER (0.78) | AGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100254983-A1 | USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2010-10-07 | — | — | US | claimed |
| WO-2008153957-A1 | USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-12-18 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100254983-A1 | USES OF RAGE ANTAGONISTS FOR TREATING OBESITY AND RELATED DISEASES | AGER, LDLR, ADIPOR1 | AGER 1/4885CXCR1 594/4885ATP4A 3056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.